Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05130983
Recruitment Status : Not yet recruiting
First Posted : November 23, 2021
Last Update Posted : December 22, 2021
Information provided by (Responsible Party):
Direct Biologics, LLC

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : January 1, 2024
Estimated Study Completion Date : March 1, 2024